Central Institute of Isotope Science, Hokkaido University, Sapporo, Japan.
Int J Oncol. 2013 Mar;42(3):823-30. doi: 10.3892/ijo.2013.1781. Epub 2013 Jan 18.
Accurate imaging to identify hypoxic regions in tumors is key for radiotherapy planning. [F-18]‑fluoro-misonidazole ([F-18]-FMISO) is widely used for tumor hypoxia imaging and has the potential to optimize radiotherapy planning. However, the biological characteristics of intratumoral [F-18]-FMISO distribution have not yet been fully investigated. In hypoxic cells, the hypoxia-inducible factor-1 (HIF-1) target proteins that induce cellular proliferation and glucose metabolism, glucose transporter-1 (Glut-1) and hexokinase-II (HK-II), are upregulated. In this study, we determined the intratumoral distribution of [F-18]-FMISO by autoradiography (ARG) and compared it with pimonidazole uptake, expression of Glut-1, tumor proliferative activity (Ki-67 index) and glucose metabolism ([C-14]2-fluoro-2-deoxy-D-glucose uptake; [C-14]-FDG) in a glioma rat model. Five C6 glioma‑bearing rats were injected with [F-18]-FMISO and [C-14]-FDG. After 90 min, the rats were injected with pimonidazole and 60 min later, the rats were sacrificed and tumor tissues were sectioned into slices. The adjacent slices were used for ARG and immunohistochemical (IHC) analyses of pimonidazole, Glut-1 and Ki-67. [F-18]-FMISO ARG images were divided into regions of high [F-18]-FMISO uptake (FMISO+) and low [F-18]-FMISO uptake (FMISO-). Pimonidazole and Glut-1 expression levels, Ki-67 index and [C-14]-FDG distribution were evaluated in the regions of interest (ROIs) placed on FMISO+ and FMISO-. [F-18]-FMISO distribution was generally consistent with pimonidazole distribution. The percentage of positively stained areas (% positive) of Glut-1 in FMISO+ was significantly higher compared to FMISO- (24 ± 8% in FMISO+ and 9 ± 4% in FMISO-; P<0.05). There were no significant differences in Ki-67 index and [C-14]-FDG uptake between FMISO+ and FMISO- (for Ki-67, 10 ± 5% in FMISO+ and 12 ± 5% in FMISO-, P=ns; for [C-14]-FDG, 1.4 ± 0.3% ID/g/kg in FMISO+ and 1.3 ± 0.3% ID/g/kg in FMISO-, P = ns). Intratumoral [F-18]-FMISO distribution reflected tumor hypoxia and expression of the hypoxia‑related gene product Glut-1; it did not, however, reflect tumor proliferation or glucose metabolism. Our findings help elucidate the biological characteristics of intratumoral [F-18]-FMISO distribution that are relevant to radiotherapy planning.
准确识别肿瘤缺氧区域对于放疗计划至关重要。[F-18] - 氟米索硝唑([F-18]-FMISO)广泛用于肿瘤缺氧成像,具有优化放疗计划的潜力。然而,肿瘤内[F-18]-FMISO 分布的生物学特性尚未得到充分研究。在缺氧细胞中,诱导细胞增殖和葡萄糖代谢的缺氧诱导因子-1 (HIF-1) 靶蛋白葡萄糖转运蛋白-1 (Glut-1) 和己糖激酶-II (HK-II) 上调。在这项研究中,我们通过放射自显影 (ARG) 确定了肿瘤内[F-18]-FMISO 的分布,并将其与在胶质瘤大鼠模型中吡莫硝唑摄取、Glut-1 表达、肿瘤增殖活性 (Ki-67 指数) 和葡萄糖代谢 ([C-14]2-氟-2-脱氧-D-葡萄糖摄取;[C-14]-FDG) 进行了比较。5 只 C6 胶质瘤荷瘤大鼠注射[F-18]-FMISO 和[C-14]-FDG。90 分钟后,大鼠注射吡莫硝唑,60 分钟后处死大鼠并将肿瘤组织切成切片。相邻的切片用于 ARG 和吡莫硝唑、Glut-1 和 Ki-67 的免疫组织化学 (IHC) 分析。[F-18]-FMISO ARG 图像分为高[F-18]-FMISO 摄取 (FMISO+) 和低[F-18]-FMISO 摄取 (FMISO-) 区域。在置于 FMISO+和 FMISO-的感兴趣区域 (ROI) 中评估吡莫硝唑和 Glut-1 表达水平、Ki-67 指数和 [C-14]-FDG 分布。[F-18]-FMISO 分布通常与吡莫硝唑分布一致。FMISO+中 Glut-1 阳性染色面积的百分比 (%阳性)明显高于 FMISO-(FMISO+中为 24±8%,FMISO-中为 9±4%;P<0.05)。FMISO+和 FMISO-之间 Ki-67 指数和 [C-14]-FDG 摄取无显著差异(对于 Ki-67,FMISO+中为 10±5%,FMISO-中为 12±5%;P=ns;对于 [C-14]-FDG,FMISO+中为 1.4±0.3%ID/g/kg,FMISO-中为 1.3±0.3%ID/g/kg;P=ns)。肿瘤内[F-18]-FMISO 分布反映了肿瘤缺氧和缺氧相关基因产物 Glut-1 的表达;然而,它并不能反映肿瘤增殖或葡萄糖代谢。我们的研究结果有助于阐明与放疗计划相关的肿瘤内[F-18]-FMISO 分布的生物学特性。